Applicant, as named in the Orange Book

Tris Pharma Inc

Next listed expiry: Dyanavel Xr on 7 Sep 2036. 6 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Dyanavel Xr NDA 208147 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	7 Sep 2036 patent	patent
Dyanavel Xr 10 NDA 210526 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	11 Feb 2040 patent, carve-out possible	patent, carve-out possible
Dyanavel Xr 15 NDA 210526 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	11 Feb 2040 patent, carve-out possible	patent, carve-out possible
Dyanavel Xr 20 NDA 210526 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	11 Feb 2040 patent, carve-out possible	patent, carve-out possible
Dyanavel Xr 5 NDA 210526 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	11 Feb 2040 patent, carve-out possible	patent, carve-out possible
Onyda Xr NDA 217645 clonidine hydrochloride	clonidine hydrochloride	28 Jul 2041 patent	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.